The agents concerned are IV injections of gadobenic acid, gadodiamide, gadopentetic acid and gadoversetamide, which are given to patients to enhance images from MRI body scans. Although no symptoms or diseases linked to gadolinium in the brain have been reported, the PRAC took a precautionary approach, noting that data on the long-term effects in the brain are limited.
Upon receipt of the grounds for their requests, the PRAC will start a re-examination, which is expected to conclude in July 2017.